Opinion|Videos|November 4, 2024
Managing Recurrent Endometrial Cancer: Treatment Strategies and RUBY Trial Insights
Panelists review available treatment options for recurrent endometrial cancer, discussing their typical treatment approaches and the factors influencing treatment selection. Panelists also address insights from the RUBY trial, its updates, and the expanded FDA indication for dostarlimab, including the implications of these developments on treatment strategies and the potential benefits and challenges of broader use in patients.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly review the available treatment options for recurrent endometrial cancer.
- What is your typical treatment approach for patients with recurrent endometrial cancer, and what factors drive your treatment selection?
- In which patients do you opt for single-agent immunotherapy (IO) vs chemotherapy + IO, and what is your underlying rationale?
- Talking points: RUBY trial, part 2 of RUBY trial, GY018, DUO-E
- Dostarlimab, durvalumab + carboplatin + paclitaxel +/- olaparib, pembrolizumab
- Briefly comment on recent data updates presented for the RUBY trial and offer insights into the expanded FDA indication for dostarlimab in endometrial cancer.
- Briefly comment on key takeaways from extended efficacy and safety data leading to the expanded approval.
- How does the expanded indication approved for dostarlimab impact your treatment approach for advanced or recurrent endometrial cancer?
- What are the potential benefits and challenges of using dostarlimab in a broader patient population?
Advertisement
Related to this article
Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.
Benjamin Weinberg, MD, discusses the FDA approval of daraxonrasib, RASolute 302 survival data, safety considerations, and future RAS-targeted therapies in pancreatic cancer.
Half of lenalidomide-refractory patients with 1 to 3 prior lines remained alive and progression free at least 5 years after a single cilta-cel infusion.
Andrew Kuykendall, MD, discusses the FDA approval of rusfertide and how to apply it in clinical practice for polycythemia vera management.
An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.
Jason Hafron, MD, discusses the emotional, clinical, and financial burden of false positive cancer screening results and improved risk stratification.
Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
The sNDA for elinzanetant seeks FDA approval for moderate-to-severe vasomotor symptoms in women receiving endocrine therapy for HR-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
China's NMPA Approves Pirtobrutinib Across CLL
2
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
Calculating the Real Cost of False Positive Findings in Cancer Screening
5